Elevated LDL cholesterol causes cardiovascular disease
7 events · 3 assessments · 3 decisions
Reassessed
Triggered by the randomized-trials subclaim recording its first assessment (verified). This is confirmatory: the claim was already verified on external synthesis (2017 EAS consensus), and the change means two of three supporting pillars now carry independent verified status in-graph. No status change; nudged confidence 0.93 -> 0.94 to reflect the strengthened in-graph foundation, credence unchanged at 0.97. Kept verified. Did not re-decompose; existing three-pillar structure remains apt. Importance left at 0.8 (foundational cardiology claim, heavily consulted, contested only by a fringe minority) which remains well calibrated. No dependent notification: the change here is not material (dependents were already told the underlying evidence stood), so no propagation needed.
Reassessed: still Verified
verdict confidence 0.93 → 0.94 · credence 0.97
Reassessed (status unchanged: verified)
Trigger was subclaim_change: the Mendelian randomization pillar was assessed for the first time as verified (0.92/0.97). Reviewed the parent's full context: the claim was already verified (0.93/0.97) on the convergence of three independent evidence lines (MR, cross-drug-class RCTs, arterial-wall mechanism) plus the 2017 EAS consensus synthesis. The change is confirmatory, not material to the status: the prior verdict already treated the MR evidence as sound. Confirmed via get_claim_details that the MR subclaim's content matches the pillar relied upon. Refreshed the reader-facing assessment and reasoning trace to reflect the now-verified MR pillar while holding status verified, confidence 0.93, credence 0.97. Importance left at 0.8, appropriate for a heavily-consulted, publicly (if fringe-) contested central cardiovascular claim; no structural change needed (decomposition remains the standard three-line causal case). Did not notify dependent stewards because the parent's status and numbers are unchanged, so no material change propagates downstream.
Reassessed: still Verified
verdict confidence 0.93 · credence 0.97
Structured and assessed
First pass. Set importance to 0.8 (from Extractor prior 0.4): high consequence-if-wrong (underwrites statins, lipid guidelines, dietary advice) plus live public contestation, though scientific consensus is firm; placed near central band but below 0.9 since the consensus is not genuinely in doubt. Decomposed into the canonical three-line causal case under a single "for" argument: Mendelian randomization (novel, created, importance 0.4), proportional RCT benefit across drug classes (novel, created, 0.4), and arterial-wall mechanism (novel, created, 0.3). match_claim returned no existing nodes for any of the three (graph neighborhood is dominated by egg/dietary-cholesterol claims). Considered but did not mint an "against" subclaim: the skeptic position is essentially the negation of this claim (one node) plus general biomarker-caution, which is addressed in prose; forcing it as structure would create false parity. Assessed verified (confidence 0.93, credence 0.97) on the 2017 EAS Consensus Statement synthesis plus MR and RCT evidence, after an adversarial pass against the cholesterol-skeptic objections (statin pleiotropy, elderly inverse association), both of which fail against the MR-plus-non-statin-RCT evidence.
Assessed Verified
verdict confidence 0.93 · credence 0.97
Elevated LDL cholesterol is established as a cause of atherosclerotic cardiovascular disease, not merely a marker of it. The conclusion rests on three independent bodies of evidence that converge: genetic (Mendelian randomization) studies, in which naturally randomized LDL-affecting variants isolate LDL's effect from confounding and reverse causation; interventional evidence from randomized trials showing that lowering LDL reduces cardiovascular events roughly in proportion to the reduction achieved, and doing so across drug classes with different mechanisms (statins, ezetimibe, PCSK9 inhibitors); and mechanistic evidence that LDL particles retained in the arterial wall initiate and drive plaque formation. A 2017 European Atherosclerosis Society consensus panel synthesizing more than 200 cohort studies, Mendelian randomization studies, and randomized trials, together comprising over two million participants and more than 150,000 events, concluded that this evidence satisfies the standard criteria for causality. The relationship is dose-dependent and cumulative: risk tracks LDL log-linearly with no clear lower threshold, and longer exposure to lower LDL yields larger benefit. A vocal minority of "cholesterol skeptics" continues to dispute the causal role, typically arguing that statin benefits reflect non-LDL ("pleiotropic") effects or citing inverse LDL-mortality associations in some elderly cohorts. These objections are answered within the mainstream literature: benefit from non-statin LDL-lowering agents rules out statin-specific pleiotropy, and the elderly associations are attributable to reverse causation, where illness lowers cholesterol. The scientific consensus is not genuinely in doubt; the persistent contestation is largely public rather than within cardiology.
Claim entered the graph